Alembic Pharmaceuticals Ltd
Thu 13/03/2025,15:59:6 | NSE : APLLTD
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 813.20
Previous Close
₹ 805.90
Volume
120379
Mkt Cap ( Rs. Cr)
₹16262.65
High
₹ 836.00
Low
₹ 800.25
52 Week High
₹ 1303.90
52 Week Low
₹ 725.20
Book Value Per Share
₹ 248.68
Dividend Yield
1.32
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Alembic Pharmaceuticals Ltd
Your Vote -
Buy
68.15%
Hold
15.92%
Sell
15.92%
68.15%
157 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
827.35
16
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
16
Option Chain
Analyzes market sentiment, predicts Alembic Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Alembic Pharma’s Vadodara Bioequivalence facility completes USFDA inspection
-
Alembic Pharmaceutic - General Updates
-
Alembic Pharmaceutic - Completion Of USFDA Inspection At Alembic Pharmaceuticals Limited'S Bioequivalence Facility At Vadodar
-
Alembic Pharmaceutic - Copy of Newspaper Publication
-
Alembic Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Alembic Pharmaceutic - General Updates
-
Alembic Pharmaceutic - Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Solid Oral Form
-
Alembic Pharmaceutic - Copy of Newspaper Publication
-
Alembic Pharmaceutic - Notice Of Shareholders Meetings-XBRL
-
Alembic Pharmaceutic - Shareholders meeting
-
Alembic Pharmaceutic - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Alembic Pharmaceutic - Change in Management
-
Alembic Pharmaceutic - General Updates
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management
-
Alembic Pharmaceutic - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations,
-
Alembic Pharmaceutic - Analysts/Institutional Investor Meet/Con. Call Updates
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Alembic Pharmaceutic - Copy of Newspaper Publication
-
Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Alembic Pharmaceutic - Retirement
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Retirement
-
Alembic Pharmaceutic - Integrated Filing- Financial
-
Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Alembic Pharmaceutic - Appointment
-
Alembic Pharmaceutic - Investor Presentation
-
Alembic Pharmaceutic - Press Release
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Alembic Pharmaceutic - Financial Result Updates
-
Alembic Pharmaceutic - Outcome of Board Meeting
-
Alembic Pharmaceutic - Board Meeting Outcome for Outcome Of The Board Meeting
-
Alembic Pharmaceutic - Integrated Filing (Financial)
-
Alembic Pharmaceutic Q3 net profit down 63.21% at Rs 85.81 cr
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Directorate
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Alembic Pharmaceutic - Results For The Quarter And Nine Months Ended 31St December, 2024
-
Alembic Pharmaceutic - Copy of Newspaper Publication
-
Alembic Pharmaceutic - Board Meeting Intimation
-
Alembic Pharmaceutic - Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Nine Months E
-
Alembic Pharmaceutic has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024
-
Alembic Pharmaceutic - Press Release
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Alembic Pharmaceutic - Resignation
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management
-
Alembic Pharmaceutic - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Alembic Pharmaceutic - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Alembic Pharmaceutic - Change in Management
-
Alembic Pharmaceutic - Updates
-
Alembic Pharmaceutic - Intimation For Change Of Name Of Registrar And Share Transfer Agent ('RTA') Of The Company
-
Alembic Pharmaceutic - Announcement under Regulation 30 (LODR)-Change in Management
-
Alembic Pharmaceutic - Trading Window-XBRL
-
Alembic Pharmaceutic - Trading Window
-
Alembic Pharmaceuticals gets USFDA nod for generic anti-epileptic drug
-
Alembic Pharmaceutic - Press Release
-
Alembic Pharmaceutic - Giving guarantees/indemnity/ becoming a surety for third party
-
Alembic Pharma receives USFDA approval for Brexpiprazole tablets
-
Alembic Pharma gets USFDA nod for Divalproex Sodium Delayed Release Capsules
-
Alembic Pharma gets USFDA nod for Olopatadine Hydrochloride Ophthalmic Solution.
-
Alembic Pharmaceuticals
-
Alembic Pharma gets final USFDA nod for alcaftadine ophthalmic solution
-
Alembic Pharmaceuticals
-
Alembic Pharmaceuticals
-
Alembic Pharma gets final USFDA nod for Dabigatran Etexilate Capsules
-
Alembic Pharma
-
Alembic Pharmaceuticals
-
Alembic Pharma gets tentative USFDA nod for Ivosidenib Tablets
-
Alembic Pharmaceuticals gets USFDA nod for Sacubitril and Valsartan Tablets.
-
Alembic Pharma's Vadodara unit receives an establishment inspection report from USFDA
-
Alembic Pharmaceuticals
-
Alembic Pharma receives tentative USFDA approval for antidepressant tablets
-
Alembic Pharma
-
Alembic Pharma gets USFDA approval for Prazosin Hydrochloride Capsules
-
Alembic Pharma gets USFDA approval for colon cancer injection
-
Alembic Pharmaceuticals
-
Alembic Pharmaceuticals
-
Alembic Pharmaceutical
-
Alembic Pharma gets final USFDA nod for Docetaxel Injection USP
-
Alembic Pharma gets tentative USFDA nod for Acalabrutinib Capsules
-
Alembic Pharma gets USFDA final nod for Fesoterodine Fumarate Extended-Release tablets
-
Alembic Pharma
-
Alembic Pharma gets USFDA final nod for Fulvestrant Injection
-
Alembic Pharma gets final USFDA nod for Desonide Cream
-
Alembic Pharma gets final USFDA nod for Diclofenac Sodium Topical Solution
-
Alembic Pharma
-
Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules
-
Alembic Pharmaceuticals gets USFDA final nod for Chlorthalidone Tablets USP
-
Alembic Pharma gets USFDA nod for Adapalene and Benzoyl Peroxide Topical Gel
-
Alembic Pharma gets USFDA nod for Diclofenac Sodium Topical Gel
-
Alembic Pharmaceuticals
-
Alembic Pharmaceuticals receives USFDA Tentative Approval for Dasatinib Tablets
-
Alembic Pharmaceuticals
-
Alembic Pharma gets final USFDA nod for Pirfenidone tablets
-
Alembic Pharma receives final USFDA nod for Arformoterol Tartrate inhalation solution
-
Alembic Pharma arm gets USFDA final nod for Clobetasol Propionate Foam
-
Alembic gets USFDA nod to market generic drug
-
Alembic Pharma arm get USFDA final nod for Lidocaine & Prilocaine cream USP
-
Alembic Pharma gets tentative USFDA nod for Dabigatran Etexilate Capsules
-
Alembic Pharma to acquire 40% stake held by Orbicular Pharma
-
Alembic Pharma
-
Alembic Pharma gets final USFDA nod for Lacosamide Tablets USP
-
Alembic Pharmaceuticals receives USFDA tentative approval for Macitentan Tablets
-
Alembic Pharma’s JV, Aleor Derma gets USFDA nod for Ointment
-
Q3FY2022 Results - Alembic Pharmaceuticals
-
Alembic Pharmaceuticals
-
Alembic Pharma gets tentative USFDA nod for Fesoterodine Fumarate Tablets
-
Alembic Pharmaceuticals
-
Alembic Pharma receives USFDA tentative nod for Dronedarone Tablets
-
Alembic Pharma receives USFDA tentative nod for Dronedarone Tablets
-
Viewpoint - Alembic Pharmaceuticals
-
Viewpoint - Alembic Pharmaceuticals
-
Alembic Pharma
-
Alembic Pharma gets US regulator's nod for anti-Parkinson's drug
-
Alembic Pharmaceuticals gets USFDA nod for antibiotic drug
-
Alembic Pharma
-
Alembic Pharmaceuticals
-
Alembic Pharma
-
Alembic Pharma gets tentative USFDA nod for Hypertension drug
-
Alembic Pharma gets tentative USFDA nod for Dabigatran Etexilate Capsules
-
Alembic Pharma gets USFDA nod for formoterol Fumarate Inhalation Solution
-
Alembic Pharma JV Aleor Derma gets USFDA nod for Mupirocin Cream
-
Alembic Pharmaceuticals
-
Alembic Pharma's JV Aleor Derma gets US FDA nod for Metronidazole Gel USP
-
Alembic Pharma gets final USFDA nod for Clomipramine Hydrochloride Capsules
-
Alembic Pharmaceuticals
-
Alembic Pharmaceuticals announces USFDA final approval for Erlotinib Tablets
-
Alembic Pharma gets USFDA nod for antidepressant drug
-
Alembic Pharma gets USFDA nod for generic of Nitrofurantoin Capsules
-
Alembic Pharma's JV Aleor Dermaceuticals gets USFDA final nod
-
Alembic Pharma gets USFDA final nod for Lurasidone Hydrochloride Tablets
-
Alembic Pharma gets final nod from USFDA
-
Alembic Pharma gets USFDA nod for Doxepin Hydrochloride Capsules
-
Alembic Pharma’s JV Aleor Derma gets tentative US FDA nod
-
Alembic Pharma's JV Aleor Derma gets USFDA nod for Testosterone Gel
-
Alembic Pharmaceuticals
-
Alembic Pharma arm gets USFDA nod Treprostinil Injection
-
Alembic Pharma's unit gets five observations from USFDA
-
Alembic Pharma gets USFDA nod for Midodrine Hydrochloride Tablets
-
Alembic Pharma gets USFDA nod for Asenapine Sublingual Tablets
-
Alembic Pharma gets USFDA nod for Metolazone Tablets
-
Alembic Pharma gets USFDA approval for testosterone gel
-
Alembic Pharma gets final nod from USFDA
-
Alembic Pharmaceuticals gets USFDA final nod for Fenofibrate Capsules
-
Alembic Pharma gets USFDA nod for Amantadine Hydrochloride Tablets, 100 mg.
-
Alembic Pharma enters into agreement with Curon Biopharma
-
Alembic Pharmaceuticals gets USFDA Tentative nod for Treprostinil Injection
-
Alembic Pharma receives USFDA approval for Desonide lotion
-
Alembic Pharma-Aleor JV gets tentative USFDA nod for anti-fungal, Tavaborole topical solution
-
Alembic Pharmaceuticals
-
Alembic Pharma gets USFDA nod for Vardenafil Hydrochloride Tablets
-
Alembic Pharma board approves raising up to Rs. 1,000 cr via QIP
-
Alembic Pharma gets tentative USFDA nod for Empagliflozin & Metformin Hydrochloride tablets
-
Alembic Pharma gets USFDA nod for Doxycycline Hyclate tablets, used to treat chest infection
-
Alembic Pharmaceuticals
-
Alembic Pharma's JV, Aleor Dermaceuticals receives USFDA final nod for Adapalene Gel USP
-
Alembic Pharmaceuticals receives USFDA Final Approval for Deferasirox Tablets
-
Alembic Pharma's JV Aleor Derma gets USFDA nod for Clobetasol Propionate Shampoo
-
Alembic Pharmaceuticals gains after USFDA nod
-
Alembic Pharmaceuticals JV gets EIR for its Karakhadi formulations facility
-
Alembic Pharmaceuticals
-
Alembic Pharma gets USFDA tentative nod for ANDA
-
Alembic Pharmaceuticals receives EIR from USFDA
-
USFDA inspects Alembic Pharma's Panelav facility
-
Alembic Pharmaceuticals declares dividend
-
Alembic Pharma gets USFDA nod for Doxycycline Hyclate Tablets USP, 20 mg
-
Alembic Pharma gets USFDA nod for anti-bacterial drug
-
Alembic Pharma gets USFDA nod for anti-bacterial drug
-
Alembic Pharma gets USFDA nod for Bosentan Tablets
-
Alembic Pharma gets USFDA nod for Bimatoprost Ophthalmic Solution
-
Alembic Pharma gets two observations for Karkhadi plant
-
Alembic Pharmaceuticals
-
Alembic Pharma gets USFDA tentative nod for Empagliflozin Tablets
-
Alembic Pharmaceuticals
-
Alembic Pharma gets USFDA nod for an anti-depression drug
-
Alembic Pharma
-
Alembic Pharma up on successful USFDA inspection
-
Alembic Pharma gets USFDA nod for a generic of Travatan solution
-
Alembic Pharma, Orbicular Pharma's JV Aleor Derma gets EIR from USFDA
-
Alembic Pharma JV gets USFDA nod
-
Alembic Pharmaceuticals gets USFDA nod
-
Alembic Pharma's JV gets USFDA nod for ointment
-
Alembic Pharma JV gets USFDA nod Clobetasol Propionate Spray
-
Alembic Pharma JV ges USFDA nod Clobetasol Propionate Spray
-
Alembic Pharma JV ges USFDA nod Clobetasol Propionate Spray
-
Alembic+Pharma+JV+ges+USFDA+nod+Clobetasol+Propionate+Spray
-
Alembic Pharma gets USFDA nod for Dorzolamide Hydrochloride Ophthalmic Solution
-
Alembic Pharma gets USFDA nod for Bimatoprost Ophthalmic Solution
-
Alembic Pharmaceuticals gets USFDA tentative nod for Dapagliflozin Tablets
-
Alembic Pharma gets USFDA nod for Clonazepam orally disintegrating tablets
-
Alembic Pharma gets USFDA nod for Oseltamivir Phosphate Capsules USP
-
Alembic Pharmaceuticals gets USFDA nod for Bromfenac Ophthalmic Solution
-
Alembic Pharma raises fund via NCDs
-
Alembic Pharma gets USFDA nod for Carbidopa, levodopa ER tablets
-
Alembic Pharmaceuticals receives USFDA nod for Solifenacin Succinate Tablets
-
Alembic Pharma-Aleor JV gets EIR from USFDA for Karakhadi unit
-
Alembic Pharma gets USFDA nod for Teriflunomide Tablets
-
Alembic Pharma gets USFDA nod for Bimatoprost Ophthalmic Solution
-
Alembic Pharma gets USFDA nod for Tadalafil tablets
-
Alembic Pharmaceuticals gets USFDA nod for ANDA
-
Alembic Pharma JV Aleor gets FDA nod for Clobetasol Ointment
-
Alembic Pharma gets USFDA nod for Acetazolamide Extended-Release Capsules
-
Alembic Pharma gets USFDA for eye drops
-
Alembic Pharma gets USFDA approval for Parkinson's drug
-
Alembic gains after USFDA inspection at Panelav
-
Alembic Pharma gets USFDA nod for treatment of allergic conjunctiviti's
-
Alembic Pharma gets USFDA nod for drug to lower blood pressure
-
Alembic Pharma gets USFDA nod for peptic ulcer drug
-
Alembic Pharma gets USFDA nod for Diabetes drug
-
Alembic Pharma has 77 ANDA nod from USFDA
-
Alembic Pharma gets USFDA nod for Bimatoprost
-
Alembic Pharma receives EIR for Karakhadi API facility
-
Alembic Pharma up 2% on EIR from USFDA
-
Alembic Pharma gets USFDA nod for schizophrenia drug
-
Alembic Pharma gets EIR for Panelav facility
-
APL gets USFDA nod for Doxycycline Hyclate capsules
-
Alembic Pharma gets USFDA nod for anti-depression drug
-
Alembic Pharma gets 3 observations for Gujarat plant
-
Alembic Pharma to have a board meeting to consider buyback
-
Alembic Pharma completes US-based Orit Lab acquisition
-
Alembic Pharma sell its formulations manufacturing facility at Baddi
-
Alembic Pharma gains on USFDA nod for new drug
-
Alembic gets tentative USFDA nod for erectile dysfunction drug
-
Alembic Pharma gets USFDA nod for Candesartan Cilexetil Tablets
Key fundamentals
Evaluate the intrinsic value of Alembic Pharmaceuticals Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 5328.95 | 5049.36 | 5920.33 | 5454.15 | 5033.05 |
Liabilities | 5328.95 | 5049.36 | 5920.33 | 5454.15 | 5033.05 |
Equity | 39.31 | 39.31 | 39.31 | 39.31 | 37.7 |
Gross Profit | 998.52 | 664.35 | 908.8 | 1572.23 | 1202.9 |
Net Profit | 666.48 | 346.73 | 543.55 | 1175.39 | 969.4 |
Cash From Operating Activities | 772.77 | 730.25 | 545.26 | 1485.3 | 539.75 |
NPM(%) | 11.34 | 6.73 | 10.79 | 23.26 | 23.45 |
Revenue | 5874.06 | 5149 | 5035.41 | 5051.44 | 4132.55 |
Expenses | 4875.54 | 4484.65 | 4126.61 | 3479.21 | 2929.65 |
ROE(%) | 13.63 | 7.09 | 11.11 | 24.04 | 19.83 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|---|---|---|---|
15 Jul 2024 | 11 | 550 | 1.33 | 1001.35 |
17 Aug 2022 | 10 | 500 | 1.33 | 786.6 |
19 Jul 2021 | 14 | 700 | 1.33 | 1006.1 |
16 Mar 2020 | 3 | 150 | 1.33 | 661.2 |
16 Mar 2020 | 7 | 350 | 1.33 | 656.25 |
18 Jul 2019 | 5.5 | 275 | 1.33 | 551.45 |
18 Jul 2018 | 4 | 200 | 1.33 | 482.25 |
11 Jul 2017 | 4 | 200 | 1.33 | 605.1 |
20 Jul 2016 | 4 | 200 | 1.33 | 619.4 |
22 Jul 2015 | 3.5 | 175 | 1.33 | 470.75 |
17 Jul 2014 | 3 | 150 | 1.33 | 297.25 |
29 Jul 2013 | 2.5 | 125 | 1.33 | 117.6 |
31 Jul 2012 | 1.4 | 70 | 1.33 | 55.1 |
Peers
Other companies within the same industry or sector that are comparable to Alembic Pharmaceuticals Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 808.20 | -1.14 | 11.41 | 472.53 | 1321.50 | 1.42 |
Lotus Eye Hospital and Institute Ltd | 57.06 | -0.77 | 237.75 | 1721.83 | 14.01 | 0.88 |
Vaishali Pharma Ltd | 12.12 | -5.90 | 606.00 | 887.50 | 2.31 | 0.00 |
Astec Lifesciences Ltd | 653.90 | -5.55 | 0.00 | 1623.54 | -239.30 | 0.00 |
Company Info
2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma 2017 -Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder. -Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs. -Alembic gets FDA tentative nod for erectile dysfunction drug. -Alembic Pharma gets USFDA nod for anti-bacterial drug. -Alembic Pharma completes acquisition of Orit Laboratories. 2018 -Alembic Pharma gets USFDA nod for ophthalmic solution. -Alembic Pharma joint venture Aleor Dermaceuticals has received approval from the US health regulator for ointment which is used for temporary relief of pain. -Alembic Pharmaceuticals has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder. -Alembic Pharma gets tentative USFDA nod for ophthalmic solution. -Alembic bags approval for Bupropion Hydrochloride Tablets. 2019 -Alembic Pharma gets USFDA final nod for Travoprost Ophthalmic Solution. -Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment drug. - Alembic Pharma gets USFDA nod for intraocular pressure reduction drug. -Alembic Pharma gets USFDA nod for glaucoma treatment drug. 2020 -Alembic Pharma receives USFDA approval for Asenapine Sublingual Tablets. -Alembic Pharma gets final USFDA nod for eye drops solution. -Alembic Pharmaceuticals receives USFDA approval for ANDA Amantadine Hydrochloride Tablets. -Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression. -Alembic Pharma gets final USFDA nod for Fenofibrate tablets. 2021 -Alembic receives USFDA tentative approval for Selexipag Tablets. -Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. -Alembic Pharma gets USFDA nod for cancer treatment drug. -Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP. 2022 -Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. -Alembic Pharma gets USFDA nod for Entacapone tablets. -Alembic Pharmaceuticals gets US FDA nod for antibiotic drug. 2023 -Alembic has a cumulative total of 182 ANDA approvals from USFDA. 2024 -Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. -Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. - Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg
2011 Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was originally incorporated on 16th June, 2010 in the name and style 'Alembic Pharma Limited', under the Companies Act, 1956 and had received the Certificate of Commencement of business on 1st July, 2010. The company changed its name from Alembic Pharma Limited to Alembic Pharmaceuticals Limited and the Registrar of Companies, Gujarat has approved the change of name and issued a fresh certificate of incorporation consequent upon change of name on 12th March, 2011. 2012 Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiqr). Alembic Pharmaceuticals Limited enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. 2013 -Alembic gets USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its product in USA. 2014 -"Alembic announces joint venture with Adwiya Mami SARL Algeria through its wholly owned Subsidiary - Alembic Global Holding S.A.". 2015 -Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with Novartis 2016 - Alembic Pharma inks JV agreement with Orbicular Pharma 2017 -Alembic Pharmaceuticals partners with Breckenridge Pharma launching tablets used in the treatment of major depressive disorder. -Alembic Pharma gets USFDA nod for generic antidepressant and anti-hypertension drugs. -Alembic gets FDA tentative nod for erectile dysfunction drug. -Alembic Pharma gets USFDA nod for anti-bacterial drug. -Alembic Pharma completes acquisition of Orit Laboratories. 2018 -Alembic Pharma gets USFDA nod for ophthalmic solution. -Alembic Pharma joint venture Aleor Dermaceuticals has received approval from the US health regulator for ointment which is used for temporary relief of pain. -Alembic Pharmaceuticals has received approval from the US health regulator to market Desenlafaxine extended-release tablets, used to treat major depressive disorder. -Alembic Pharma gets tentative USFDA nod for ophthalmic solution. -Alembic bags approval for Bupropion Hydrochloride Tablets. 2019 -Alembic Pharma gets USFDA final nod for Travoprost Ophthalmic Solution. -Alembic Pharma JV Aleor Dermaceuticals gets USFDA nod for plaque psoriasis treatment drug. - Alembic Pharma gets USFDA nod for intraocular pressure reduction drug. -Alembic Pharma gets USFDA nod for glaucoma treatment drug. 2020 -Alembic Pharma receives USFDA approval for Asenapine Sublingual Tablets. -Alembic Pharma gets final USFDA nod for eye drops solution. -Alembic Pharmaceuticals receives USFDA approval for ANDA Amantadine Hydrochloride Tablets. -Alembic gets USFDA nod for Vilazodone Hydrochloride tablets used to treat depression. -Alembic Pharma gets final USFDA nod for Fenofibrate tablets. 2021 -Alembic receives USFDA tentative approval for Selexipag Tablets. -Alembic Pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules. -Alembic Pharma gets USFDA nod for cancer treatment drug. -Alembic Pharmaceuticals has subscribed to partnership interest in ABCD Technologies LLP. 2022 -Alembic Pharmaceuticals receives USFDA approval for Cyclophosphamide Capsules. -Alembic Pharma gets USFDA nod for Entacapone tablets. -Alembic Pharmaceuticals gets US FDA nod for antibiotic drug. 2023 -Alembic has a cumulative total of 182 ANDA approvals from USFDA. 2024 -Alembic Pharmaceuticals has received USFDA approval for generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy. -Alembic Pharmaceuticals has received USFDA approval for generic version of Paliperidone extended-release tablets indicated for the treatment of schizophrenia. - Alembic Pharmaceuticals has received USFDA approval for the abbreviated new drug application (ANDA) for Ivosidenib tablets of strength 250 mg
Read More
Parent Organisation
Alembic Pharmaceuticals Ltd.
Founded
16/06/2010
Managing Director
Mr.Chirayu Amin
NSE Symbol
APLLTDEQ
FAQ
The current price of Alembic Pharmaceuticals Ltd is ₹ 827.35.
The 52-week high for Alembic Pharmaceuticals Ltd is ₹ 836.00 and the 52-week low is ₹ 800.25.
The market capitalization of Alembic Pharmaceuticals Ltd is currently ₹ 16262.65. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Alembic Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Alembic Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Alembic Pharmaceuticals Ltd shares.
The CEO of Alembic Pharmaceuticals Ltd is Mr.Chirayu Amin, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.